


CLAIMS


1. A compound of the formula



wherein R^1 is (C_1-C_6) alkyl, optionally substituted by (C_3-C_{10}) cycloalkyl, (C_6-C_{10}) aryl, (C_1-C_{10}) heterocyclyl, or (C_1-C_{10}) heteroaryl, wherein each of said (C_1-C_6) alkyl, (C_3-C_{10}) cycloalkyl, (C_6-C_{10}) aryl, (C_1-C_{10}) heterocyclyl, or (C_1-C_{10}) heteroaryl are optionally substituted by one to three suitable moieties independently selected from the group consisting of hydroxy, halogen, CN-, (C_1-C_6) alkyl, HO (C_1-C_6) alkyl, (C_1-C_6) alkyl-NH(C=O)-, NH₂(C=O)-, (C_1-C_6) alkoxy, or (C_3-C_{10}) cycloalkyl, wherein said (C_3-C_{10}) cycloalkyl is optionally substituted by one or more moieties selected from halogen, or (C_1-C_6) alkyl-;

R^2 is hydrogen, halogen, -CN, and (C_1-C_6) alkyl, wherein said (C_1-C_6) alkyl is optionally substituted by one to three suitable moieties, independently selected from the group consisting of halo, hydroxy, amino, -CN, (C_1-C_6) alkyl, (C_1-C_6) alkoxy, -CF₃, CF₃O-, (C_1-C_6) alkyl-NH-, [(C_1-C_6)alkyl]₂-N-, (C_1-C_6) alkyl-S-, (C_1-C_6) alkyl-(S=O)-, (C_1-C_6) alkyl-(SO₂)-, (C_1-C_6) alkyl-O-(C=O)-, formyl, (C_1-C_6) alkyl-(C=O)-, and (C_3-C_6) cycloalkyl;

R^3 is a nitrogen linked (C_1-C_{10}) heterocyclyl of the formula:



wherein R^4 is independently selected from the group of suitable substituents, such as hydrogen, halo, hydroxy, -CN, HO- (C_1-C_6) alkyl, (C_1-C_6) alkyl optionally substituted with one to three fluoro, (C_1-C_6) alkoxy optionally substituted with one to three fluoro, HO₂C-, (C_1-C_6) alkyl-O-(C=O)-, R⁵R⁶N(O₂S)-, (C_1-C_6) alkyl-(O₂S)-NH-, (C_1-C_6) alkyl-O₂S-[(C_1-C_6) alkyl-N]-, R⁵R⁶N(C=O)-, R⁵R⁶N(CH₂)_m-, (C_6-C_{10}) aryl, (C_3-C_8) cycloalkyl, (C_1-C_{10}) heteroaryl, (C_1-C_{10}) heterocyclyl, (C_6-C_{10}) aryl-O-, (C_3-C_8) cycloalkyl-O-, (C_1-C_{10}) heteroaryl-O- and (C_1-C_{10}) heterocyclyl-O-; and

R^7 is independently selected from the group of suitable substituents such as hydrogen and (C_1-C_6) alkyl optionally substituted with one to three halogens, hydroxy, -CN,

(C₁-C₆)alkoxy-, (C₂-C₆)alkenoxy, (C₁-C₆)alkyl-SO₂-, NH₂-, ((C₁-C₆)alkyl)_n-N-, ((C₂-C₆)alkenyl)_n-N-, ((C₂-C₆)alkynyl)_n-N-, NH₂(C=O)-, (C₁-C₆)alkyl-(C=O)N-, ((C₁-C₆)alkyl)_n-N-(C=O)-, (C₂-C₆)alkenyl-(C=O)N-, ((C₂-C₆)alkenyl)_n-N-(C=O)-, (C₂-C₆)alkynyl-(C=O)N-, ((C₂-C₆)alkynyl)_n-N-(C=O)-, (C₁-C₆)alkyl-(C=O)-, (C₂-C₆)alkenyl-(C=O)-, (C₂-C₆)alkynyl-(C=O)-, (C₃-C₁₀)cycloalkyl-
5 (C=O)-, ((C₁-C₁₀)heterocyclyl-(C=O)-, (C₆-C₁₀)aryl-(C=O), (C₁-C₁₀)heteroaryl-(C=O), (C₁-C₆)alkyl-(C=O)O-, (C₂-C₆)alkenyl-(C=O)O-, (C₂-C₆)alkynyl-(C=O)O-, (C₁-C₆)alkyl-O(C=O)-, (C₂-C₆)alkenyl-O-(C=O)-, (C₂-C₆)alkynyl-O-(C=O)-, (C₃-C₁₀)cycloalkyl, (C₆-C₁₀)aryl, (C₁-C₁₀)heterocyclyl, and (C₁-C₁₀)heteroaryl;

wherein R⁴ and R⁷ may each be optionally substituted on any aliphatic or aromatic
10 carbon atom by one to three suitable moieties, independently selected from the group consisting of halo, hydroxy, amino, -CN, (C₁-C₆)alkyl, (C₁-C₆)alkoxy, -CF₃, CF₃O-, (C₁-C₆)alkyl-NH-, [(C₁-C₆)alkyl]₂N-, (C₁-C₆)alkyl-S-, (C₁-C₆)alkyl-(S=O)-, (C₁-C₆)alkyl-(SO₂)-, (C₁-C₆)alkyl-O-(C=O)-, formyl, (C₁-C₆)alkyl-(C=O)-, and (C₃-C₆)cycloalkyl;

R⁵ and R⁶ are each independently selected from the group consisting of hydrogen, (C₁-C₆)alkyl, HO-(C₂-C₆)alkyl and (C₃-C₈)cycloalkyl, or R⁵ and R⁶ may optionally be taken together with the nitrogen atom to which they are attached to form a 3 to 8 membered heterocycle;

n is an integer from zero to two; and

m is an integer from one to two;

20 or the pharmaceutically acceptable salts or solvates or prodrugs thereof.

2. A compound of any of the preceding claims wherein R¹ is (C₁-C₄)alkyl, optionally substituted by (C₃-C₁₀)cycloalkyl; wherein said (C₁-C₄)alkyl or (C₃-C₁₀)cycloalkyl are optionally substituted by one to three suitable moieties independently selected from the group consisting of hydroxy, halogen, CN-, (C₁-C₆)alkyl, HO(C₁-C₆)alkyl, (C₁-C₆)alkyl-NH(C=O)-, NH₂(C=O)-, (C₁-C₆)alkoxy, or (C₃-C₁₀)cycloalkyl, wherein said (C₃-C₁₀)cycloalkyl is optionally substituted by one or more moieties selected from halogen, or (C₁-C₆)alkyl-..


3. A compound of any of the preceding claims wherein R¹ is (C₁-C₄)alkyl, optionally substituted by (C₆-C₁₀)aryl; wherein said (C₁-C₄)alkyl or (C₆-C₁₀)aryl are optionally substituted by one to three suitable moieties independently selected from the group consisting of hydroxy, halogen, CN-, (C₁-C₆)alkyl, HO(C₁-C₆)alkyl, (C₁-C₆)alkyl-NH(C=O)-, NH₂(C=O)-, (C₁-C₆)alkoxy, or (C₃-C₁₀)cycloalkyl, wherein said (C₃-C₁₀)cycloalkyl is optionally substituted by one or more moieties selected from halogen, or (C₁-C₆)alkyl-.

4. A compound of any of the preceding claims wherein R² is chloro, methyl or ethyl.


35 5. A compound of any of the preceding claims wherein R³ is a nitrogen linked (C₁-C₁₀)heterocyclyl of formula (III), wherein R⁴ is hydrogen and R⁷ is independently selected from the group of suitable substituents such as hydrogen and (C₁-C₆)alkyl, wherein said (C₁-

C_6 alkyl is optionally substituted with one to three substituents independently selected from halo, hydroxy, -CN, (C_1 - C_6)alkoxy-, (C_2 - C_6)alkenoxy, (C_1 - C_6)alkyl-SO₂-, NH₂-, (C_1 - C_6)alkyl_n-N-, ((C_2 - C_6)alkenyl)_n-N-, ((C_2 - C_6)alkynyl)_n-N-, NH₂(C=O)-, (C_1 - C_6)alkyl-(C=O)N-, ((C_1 - C_6)alkyl)_n-N-(C=O)-, (C_2 - C_6)alkenyl-(C=O)N-, ((C_2 - C_6)alkenyl)_n-N-(C=O)-, (C_2 - C_6)alkynyl-
5 (C=O)N-, ((C_2 - C_6)alkynyl)_n-N-(C=O)-, (C_1 - C_6)alkyl-(C=O)-, (C_2 - C_6)alkenyl-(C=O)-, (C_2 - C_6)alkynyl-(C=O)-, (C_3 - C_{10})cycloalkyl-(C=O)-, ((C_1 - C_{10})heterocyclyl-(C=O)-, (C_6 - C_{10})aryl-(C=O), (C_1 - C_{10})heteroaryl-(C=O), (C_1 - C_6)alkyl-(C=O)O-, (C_2 - C_6)alkenyl-(C=O)O-, (C_2 - C_6)alkynyl-(C=O)O-, (C_1 - C_6)alkyl-O(C=O)-, (C_2 - C_6)alkenyl-O-(C=O)-, (C_2 - C_6)alkynyl-O-(C=O)-, (C_3 - C_{10})cycloalkyl, (C_6 - C_{10})aryl, (C_1 - C_{10})heterocyclyl, and (C_1 - C_{10})heteroaryl; wherein R⁷ may
10 optionally be substituted on any ring aliphatic or aromatic carbon atom by one to three suitable moieties, independently selected from the group consisting of halo, hydroxy, amino, -CN, (C_1 - C_4)alkyl, (C_1 - C_4)alkoxy, -CF₃, CF₃O-, (C_1 - C_4)alkyl-NH-, [(C_1 - C_4)alkyl]₂-N-, (C_1 - C_4)alkyl-S-, (C_1 - C_4)alkyl-(S=O)-, (C_1 - C_4)alkyl-(SO₂)-, (C_1 - C_4)alkyl-O-(C=O)-, formyl, (C_1 - C_4)alkyl-(C=O)-, and (C_3 - C_6)cycloalkyl.
15

6. A compound of any of the preceding claims wherein R⁷ is hydrogen.
7. A compound of any of the preceding claims wherein R³ is a nitrogen linked




and R⁷ is selected from the group consisting of:




20


8. A compound of any of the preceding claims wherein R³ is a nitrogen linked (C₁-C₁₀)heterocyclyl of formula (IV), and R⁷ is




9. A compound of any of the preceding claims wherein R^3 is a nitrogen linked (C_1-C_{10})heterocyclyl of formula (IV), and R^7 is selected from the group consisting of:




5 10. A compound of any of the preceding claims wherein R³ is a nitrogen linked
(C₁-C₁₀)heterocyclyl of formula (IV), and R⁷ is



11. A compound of any of the preceding claims wherein R^3 is a nitrogen linked (C_1-C_{10})heterocyclyl of formula (IV), and R^7 is selected from:



12. A compound of any of the preceding claims wherein R³ is a nitrogen linked (C₄-C₁₀)heterocyclol of formula (IV), and R⁷ is selected from:



13. A compound selected from the group consisting of:

2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-[4-(2-hydroxy-3-methoxy-propyl)-3,5-dioxo-4,5-dihydro-3H-[1,2,4]triazin-2-yl]-benzamide;

5 2-Chloro-5-[4-(2,3-dihydroxy-propyl)-3,5-dioxo-4,5-dihydro-3H-[1,2,4]triazin-2-yl]-N-(1-hydroxy-cyclohexylmethyl)-benzamide;

 2-Chloro-N-(1-hydroxy-cycloheptylmethyl)-5-[4-(2-hydroxy-ethyl)-3,5-dioxo-4,5-dihydro-3H-[1,2,4]triazin-2-yl]-benzamide;

10 2-Chloro-5-[4-(2,3-dihydroxy-propyl)-3,5-dioxo-4,5-dihydro-3H-[1,2,4]triazin-2-yl]-N-(1-hydroxy-cycloheptylmethyl)-benzamide;

 2-Chloro-5-(4-cyanomethyl-3,5-dioxo-4,5-dihydro-3H-[1,2,4]triazin-2-yl)-N-(1-hydroxy-cycloheptylmethyl)-benzamide;

 2-Chloro-5-[4-(2-hydroxy-3-methoxy-propyl)-3,5-dioxo-4,5-dihydro-3H-[1,2,4]triazin-2-yl]-N-(1-hydroxymethyl-cycloheptylmethyl)-benzamide;

15 2-Chloro-5-[4-(2-cyano-ethyl)-3,5-dioxo-4,5-dihydro-3H-[1,2,4]triazin-2-yl]-N-(1-hydroxy-cycloheptylmethyl)-benzamide;

 N-(1-Hydroxy-cycloheptylmethyl)-5-[4-(2-hydroxy-ethyl)-3,5-dioxo-4,5-dihydro-3H-[1,2,4]triazin-2-yl]-2-methyl-benzamide;

20 2-Chloro-5-[4-(2,3-dihydroxy-propyl)-3,5-dioxo-4,5-dihydro-3H-[1,2,4]triazin-2-yl]-N-(1-hydroxy-cyclohexylmethyl)-benzamide;

 2-Chloro-N-(1-hydroxy-cycloheptylmethyl)-5-[4-(2-hydroxy-2-methyl-propyl)-3,5-dioxo-4,5-dihydro-3H-[1,2,4]triazin-2-yl]-benzamide;

 2-Chloro-N-(1-hydroxy-cyclooctylmethyl)-5-[4-(2-hydroxy-3-methoxy-propyl)-3,5-dioxo-4,5-dihydro-3H-[1,2,4]triazin-2-yl]-benzamide;

25 2-Chloro-N-(1-hydroxy-cycloheptylmethyl)-5-[4-(2-hydroxy-2-phenyl-ethyl)-3,5-dioxo-4,5-dihydro-3H-[1,2,4]triazin-2-yl]-benzamide;

- 2-Chloro-5-[3,5-dioxo-4-(3,3,3-trifluoro-2-hydroxy-propyl)-4,5-dihydro-3H-[1,2,4]triazin-2-yl]-N-(1-hydroxy-cycloheptylmethyl)-benzamide;
- 2-Chloro-5-[4-(2-hydroxy-3-methoxy-propyl)-3,5-dioxo-4,5-dihydro-3H-[1,2,4]triazin-2-yl]-N-(2-hydroxy-2-phenyl-ethyl)-benzamide;
- 5 5-(4-Carbamoylmethyl-3,5-dioxo-4,5-dihydro-3H-[1,2,4]triazin-2-yl)-2-chloro-N-(1-hydroxy-cycloheptylmethyl)-benzamide;
- 2-Chloro-N-(1-hydroxy-cycloheptylmethyl)-5-[4-(2-methoxy-ethyl)-3,5-dioxo-4,5-dihydro-3H-[1,2,4]triazin-2-yl]-benzamide;
- 10 5-[4-(2,3-Dihydroxy-propyl)-3,5-dioxo-4,5-dihydro-3H-[1,2,4]triazin-2-yl]-N-(1-hydroxy-cycloheptylmethyl)-2-methyl-benzamide;
- 5-[4-(3-Amino-2-hydroxy-propyl)-3,5-dioxo-4,5-dihydro-3H-[1,2,4]triazin-2-yl]-2-chloro-N-(1-hydroxy-cycloheptylmethyl)-benzamide; and
- 2-Chloro-N-(1-hydroxy-cycloheptylmethyl)-5-[4-(2-hydroxy-3-methoxy-propyl)-3,5-dioxo-4,5-dihydro-3H-[1,2,4]triazin-2-yl]-benzamide.
- 15 14. A pharmaceutical composition for treating a IL-1 mediated disease in a mammal in need thereof, comprising a therapeutically effective amount of a compound according to claim 1 or a salt or prodrug thereof, and a pharmaceutically acceptable carrier or diluent.
15. A method of treating an IL-1 mediated disease in a mammal in need thereof,
- 20 comprising administering to said mammal a therapeutically effective amount of a compound according to claim 1 or a salt or prodrug thereof.